|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Vascular Diseases
|
0.300 |
Biomarker
|
group |
CTD_human |
Regulation of myosin light chain kinase expression by angiotensin II in hypertension.
|
18511912 |
2008 |
|
Cerebral Edema
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Inhibition of the myosin light chain kinase prevents hypoxia-induced blood-brain barrier disruption.
|
17419808 |
2007 |
|
Vasogenic Cerebral Edema
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Inhibition of the myosin light chain kinase prevents hypoxia-induced blood-brain barrier disruption.
|
17419808 |
2007 |
|
Cytotoxic Cerebral Edema
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Inhibition of the myosin light chain kinase prevents hypoxia-induced blood-brain barrier disruption.
|
17419808 |
2007 |
|
Vasogenic Brain Edema
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Inhibition of the myosin light chain kinase prevents hypoxia-induced blood-brain barrier disruption.
|
17419808 |
2007 |
|
Cytotoxic Brain Edema
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Inhibition of the myosin light chain kinase prevents hypoxia-induced blood-brain barrier disruption.
|
17419808 |
2007 |
|
Brain Edema
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Inhibition of the myosin light chain kinase prevents hypoxia-induced blood-brain barrier disruption.
|
17419808 |
2007 |
|
Malignant tumor of colon
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
MBNL1-AS1 and MYL9 were poorly expressed in colon cancer.
|
31255531 |
2020 |
|
Colon Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
MBNL1-AS1 and MYL9 were poorly expressed in colon cancer.
|
31255531 |
2020 |
|
Cardiomyopathy, Hypertrophic, Familial
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
Our data suggest that myosin RLC phosphorylation may have important translational implications for the treatment of RLC mutations-induced HCM and possibly play a role in other disease settings accompanied by depressed Ser15-RLC phosphorylation.
|
31101927 |
2019 |
|
Malignant tumor of colon
|
0.030 |
Biomarker
|
disease |
BEFREE |
Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca<sup>2+</sup> signalling.
|
28013338 |
2017 |
|
Malignant tumor of colon
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
As an example, IG-SVM achieved a classification accuracy of 90.32% for colon cancer, which is difficult to be accurately classified, only based on three genes including CSRP1, MYL9, and GUCA2B.
|
29246519 |
2017 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Myosin light chain 9 (MYL9) is necessary for cytoskeletal dynamics and experimental metastasis, but its expression in esophageal squamous cell carcinoma (ESCC) has not been addressed.
|
28388691 |
2017 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Patients with high MYL9 expression in the tumor cells had poorer overall survival (OS) and recurrence-free survival.
|
28388691 |
2017 |
|
Colon Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
As an example, IG-SVM achieved a classification accuracy of 90.32% for colon cancer, which is difficult to be accurately classified, only based on three genes including CSRP1, MYL9, and GUCA2B.
|
29246519 |
2017 |
|
Colon Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca<sup>2+</sup> signalling.
|
28013338 |
2017 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Comparative transcriptomic analysis and real-time PCR analysis showed that expression of signaling molecules regulating several tumor properties including migration (MYL9), metastasis (CEACAM6, VEGFC, CX3CL1, CST1, CCL5, S100A9, IGF1, NOTCH3), adhesion (FN1, CEACAM1) and inflammation (TRAF2, NFκB2 and RelB) were altered in A549L6 cells.
|
26090868 |
2015 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, MYL9 was mainly expressed in the cytoplasm of stromal cells of prostate tissues, and the decreased expression of MYL9 in PCa tissues was significantly correlated with the older age of patients (P = 0.011), the higher Gleason score (P < 0.001), the advanced pathological stage (P = 0.002), the presence of metastasis (P < 0.001) and PSA failure (P = 0.001).
|
24338276 |
2014 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
And then, the expression levels of two selected genes in the down-regulated co-pathways, myosin light chain kinase (MYLK) and myosin regulatory light chain 9 (MYL9), were determined in tumor, paired paraneoplastic, and normal lung tissues.
|
25179839 |
2014 |
|
Cardiomyopathy, Hypertrophic, Familial
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
This study focuses on the aspartic acid to valine substitution (D166V) in the myosin RLC shown to be associated with a malignant phenotype of familial hypertrophic cardiomyopathy (FHC).
|
24374283 |
2014 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The significance for pVHL function of two further genes upregulated by wild-type pVHL was initially unclear, but re-expression of GNG4 (G protein gamma-4 subunit/guanine nucleotide-binding protein-4) and MLC2 (myosin light chain) in a RCC cell line suppressed tumour cell growth. pVHL regulation of CDKN1C, SPARC and GNG4 was not mimicked by hypoxia, whereas for six of 11 novel targets analysed (including DOC-2/DAB2 and MLC2) the effects of pVHL inactivation and hypoxia were similar.
|
15824735 |
2005 |
|
Cardiomyopathy, Hypertrophic, Familial
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The E22K mutation of myosin RLC that causes familial hypertrophic cardiomyopathy increases calcium sensitivity of force and ATPase in transgenic mice.
|
16076902 |
2005 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
MRCK-mediated invasion occurred via downstream signaling to effector molecules MYPT1 and MLC2.
|
30279244 |
2018 |
|
Hyperlipoproteinemia Type IIa
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
This study focuses on the aspartic acid to valine substitution (D166V) in the myosin RLC shown to be associated with a malignant phenotype of familial hypertrophic cardiomyopathy (FHC).
|
24374283 |
2014 |